Loading clinical trials...
Loading clinical trials...
A Single-arm, Multicenter, Open-label, 52-week Treatment, Extension Study to CLDT600ACN04 Study to Evaluate the Efficacy (Including Histological Improvement) and Safety in Fourth to Sixth Year of Telbivudine Treatment in Patients With Chronic Hepatitis B
Conditions
Interventions
telbivudine/LDT600
Locations
4
China
Beijing Ditan Hospital
Beijing, China
First Hospital of Peking University
Beijing, China
Peking University People's Hospital
Beijing, China
Ruijin Hospital, Affiliated to 2nd Medical university
Shanghai, China
Start Date
March 1, 2009
Primary Completion Date
April 1, 2011
Last Updated
May 4, 2012
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions